Home Search
geovax - search results
If you're not happy with the results, please do another search
GeoVax (GOVX) Down on JFK’s Continued Scale Backs to the Vaccine Sector.
Down 20% in response to news in an 8K that the Biomedical Advanced Research and Development Authority BARDA (also once known as the richest kid...
We’re Back! And We’re Adding (again), GeoVax (GOVX), the Alkaline Water Co (WTER) and...
GeoVax (GOVX) $1.64. Recent High $11.18 (BiotechStockReview)
The Alkaline Water Co. (WTER) $0.09. Recent High $0.48 (BeverageStockReview)
Society Pass (SOPA) $1.27. Recent High $6.75. (InternetStockReview)
Okay we're...
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier 44-page report, we printed it out and...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value of award to GeoVax and its CRO partner total approximately $367-388 million
BARDA-funded...
GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!
Are we happy, you betcha!
We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...
GeoVax (GOVX) Research Reports Archive
Research Report Archive
Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX).
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26 BILLION TRIFECTA...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines
ATLANTA, GA,...
GeoVax to Present at World Vaccine Congress, Thursday April 4th.
Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00...